Spexis AG
Develops therapeutics for rare diseases, oncology, and antimicrobial resistance.
SPEX | SW
Overview
Corporate Details
- ISIN(s):
- CH0106213793
- LEI:
- 391200S8HJE1I96FIG04
- Country:
- Switzerland
- Address:
- Hegenheimermattweg 125, 4123 Allschwil
- Website:
- https://www.polyphor.com/
- Sector:
- Manufacturing
Description
Spexis AG is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for rare diseases and oncology. The company leverages its expertise in macrocycle technology to create novel drug candidates designed to address high unmet medical needs. Its pipeline is advanced through a strategy that includes in-house discovery, development, in-licensing, and the acquisition of promising molecules. The primary therapeutic areas of interest include rare diseases and cancer, with an additional focus on antimicrobial resistance.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2018-04-24 07:00 |
Polyphor presents new data at ECCMID on murepavadin and on its novel class of O…
|
English | 9.6 KB | ||
| 2018-04-19 07:00 |
U.S. FDA grants Fast Track designation for Polyphor's innovative immuno-oncolog…
|
English | 8.3 KB | ||
| 2018-04-16 07:00 |
Polyphor to present data at the 28th European Congress of Clinical Microbiology
|
English | 7.3 KB | ||
| 2018-04-13 07:00 |
Polyphor successfully completes Wellcome Trust collaboration for development of…
|
English | 9.7 KB | ||
| 2018-03-27 07:00 |
Polyphor announces enrollment of first patient in Phase III clinical trial for …
|
English | 9.2 KB | ||
| 2018-03-23 11:16 |
Polyphor presents positive proof of concept data for innovative immuno-oncology…
|
English | 9.1 KB | ||
| 2018-03-09 07:00 |
Polyphor announces successful end of Phase I meeting with FDA on its innovative…
|
English | 9.1 KB | ||
| 2018-02-15 07:10 |
Polyphor AG: Polyphor enters worldwide exclusive license agreement with Santher…
|
English | 7.1 KB | ||
| 2018-01-23 19:17 |
Polyphor: Global No. 2 in the 2018 Biopharmaceuticals Antimicrobial Resistance …
|
English | 7.6 KB | ||
| 2017-10-12 09:03 |
Polyphor AG: Polyphor launches the development of an inhaled formulation of its…
|
English | 15.9 KB | ||
| 2017-07-18 09:00 |
Polyphor AG: Polyphor achieves ahead of schedule first milestone from Wellcome …
|
English | 6.2 KB | ||
| 2017-07-10 09:00 |
Polyphor AG: Polyphor contributes to the progress in understanding Neutrophil E…
|
English | 9.3 KB | ||
| 2017-05-23 15:11 |
Polyphor AG: Kalina Scott appointed new CFO of Polyphor
|
English | 5.8 KB | ||
| 2017-05-19 09:01 |
Polyphor AG: Polyphor announces successful end of phase II meeting with FDA for…
|
English | 7.8 KB | ||
| 2017-04-24 18:15 |
Polyphor AG: Outer-Membrane Protein Targeting Antibiotics (OMPTAs) - New hope a…
|
English | 9.4 KB |
Automate Your Workflow. Get a real-time feed of all Spexis AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Spexis AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Spexis AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-21 | N/A | Executive member | Other | None | N/A |
Peer Companies
